Working… Menu

Role of TLR4 in Environmental Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00671892
Recruitment Status : Completed
First Posted : May 5, 2008
Last Update Posted : July 16, 2013
Information provided by (Responsible Party):
John Sundy, Duke University

Brief Summary:
The overall goal of this project is to identify genes that are involved in the development of airflow obstruction and airway inflammation in asthmatics, and to determine whether polymorphisms in these differentially expressed genes predispose individuals to develop asthma. In this project, we hypothesize that polymorphisms of genes expressed by the airway epithelia in asthmatics following specific airway challenges predispose individuals to the development of asthma.

Condition or disease Intervention/treatment Phase
Asthma Biological: Lipopolysaccharide endotoxin Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 855 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Role of TLR4 in Environmental Asthma
Study Start Date : September 2001
Actual Primary Completion Date : August 2006
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Challenge

Experimental Challenge Challenge 1 saline 5000EU 10,000EU 20,000EU

Challenge 2 Saline 40,000EU 80,000EU

Biological: Lipopolysaccharide endotoxin

Delivered in nebulized form expressed in activity units(endotoxin units -EU).

Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:

Challenge One first saline then 5000 EU 10,000 EU 20,000 EU

Challenge 1 and 2 must be at least 2 weeks apart.

Challenge 2 Saline 40,000 EU 80,000 EU

Other Name: (CCRE)LPS endotoxin from E. Coli 0:113 maintained by NIH

Primary Outcome Measures :
  1. Ascertain individuals homozygous, and heterozygous for mutant TLR4 genotype, along with wild types by recruitment of healthy screening subjects in the community. [ Time Frame: completed ]

Secondary Outcome Measures :
  1. Assess the effect of TLR4 genotype on LPS endotoxin induced immune responses and assess the association of the LPS-induced immune response with LPS-induced airway responses. [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • vital signs within normal limits
  • negative methacholine challenge (non asthmatic)
  • normal PFT's, CXR, EKG
  • negative allergy skin tests (non atopic)
  • never cigarette smoker
  • no chronic illness
  • no daily meds except contraceptives
  • able and willing to sign informed consent
  • not an employee working for,or a student under the authority of the PI's

Exclusion Criteria:

  • allergic rhinitis past or present
  • chronic illness resulting in altered lung function
  • chronic daily medications
  • cigarette smoking
  • allergy to acetaminophen or albuterol
  • pregnant or nursing females
  • PFT results below cut off
  • Positive allergy skin test
  • Abnormal CXR or EKG
  • Positive methacholine challenge
  • Infection in the previous 2 weeks
  • Past or present allergen immunotherapy
  • Occupational exposure to hay or grain
  • Other medical or psychological conditions which, in the opinion of the PI, may create undue risk to the subject or interfere with the subject's ability to comply with protocol requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00671892

Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
John Sundy
Layout table for investigator information
Principal Investigator: John S Sundy, M.D., PhD. Duke University
Layout table for additonal information
Responsible Party: John Sundy, Associate Professor of Medicine, Duke University Identifier: NCT00671892    
Other Study ID Numbers: 3030-07-8R5
12496-CP-007 ( Other Identifier: NIEHS )
First Posted: May 5, 2008    Key Record Dates
Last Update Posted: July 16, 2013
Last Verified: July 2013
Keywords provided by John Sundy, Duke University:
LPS endotoxin
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases